Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Opthea Limited ( (AU:OPT) ) has shared an update.
Opthea Limited announced plans to host Investor Days in New York and Australia to discuss commercial insights and readiness plans for sozinibercept, their lead candidate for wet AMD treatment. These events will provide updates on pivotal trial data and highlight sozinibercept’s potential to improve vision outcomes and its commercial readiness when combined with anti-VEGF-A therapies, positioning Opthea as a key player in advancing retinal disease treatment.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is in pivotal Phase 3 clinical trials to enhance the efficacy of standard-of-care anti-VEGF-A therapies.
YTD Price Performance: 0%
Average Trading Volume: 17,450
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $569.6M
See more data about OPT stock on TipRanks’ Stock Analysis page.
